Hyphens Pharma International Limited

1J5

SG1EE4000006

Pharmaceuticals

Market Closed - Singapore S.E. Other stock markets 06:52:54 02/07/2024 BST			5-day change	1st Jan Change
0.275 ^SGD	0.00%		-1.79%	-3.51%

06-06	Singapore Shares Remain Flat Despite Overnight Gains in Global Markets; Zheneng Jinjiang Rises 3%	MT
06-06	Hyphens Pharma’s Subsidiary Enters Exclusive Deal with Maruho	MT

Hyphens Pharma International Limited Appoints Elaine Yeh as Business Director for Hyphens Dermatology

February 18, 2019 at 10:32 am

Hyphens Pharma International Limited announced the appointment of Elaine Yeh as Business Director for Hyphens Dermatology with effect from 18 February 2019. Reporting to the company's Executive Chairman and CEO, Lim See Wah, Elaine will lead the overall business of Hyphens Dermatology and will be responsible for achieving the overall targeted sales and profits for the business unit.

Latest news about Hyphens Pharma International Limited

Singapore Shares Remain Flat Despite Overnight Gains in Global Markets; Zheneng Jinjiang Rises 3%	06-06	MT
Hyphens Pharma’s Subsidiary Enters Exclusive Deal with Maruho	06-06	MT
Singapore Shares Drop in Red Despite Global Rally; Biolidics Surges 20% on Wider Losses in Q1	05-15	MT
Hyphens Pharma's Q1 Net Profit Nearly Doubles on Broad-Based Sales Growth; Stock Climbs 6%	05-15	MT
Hyphens Pharma International Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Hyphens Pharma International Limited Approves a Final Tax Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2023	04-25	CI
Hyphens Pharma International Limited's Equity Buyback announced on April 2, 2024, has expired.	04-24	CI
Hyphens Pharma’s Attributable Profit Narrows in 2023	04-09	MT
Hyphens Pharma International Limited Proposes Final Tax Exempt (One-Tier) Dividend	04-09	CI
Hyphens Pharma Buys Back Shares	04-03	MT
Hyphens Pharma International Limited commences an Equity Buyback Plan for 30,877,620 shares, representing 10% of its issued share capital, under the authorization approved on April 26, 2023.	04-02	CI
CGS-CIMB Adjusts Hyphens Pharma’s Price Target to SG$0.35 From SG$0.32, Keeps at Add	03-15	MT
Hyphens Pharma Obtains License to MC2's Psoriasis Cream	03-13	MT
Hyphens Pharma International Limited Signs Exclusive Distribution Agreement with Cooper Pharma, S.A	02-29	CI
Hyphens Pharma International Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Hyphens Pharma Strikes Distribution Deal With 7-Eleven Singapore	02-13	MT
Hyphens Pharma Partners 7-Eleven to Offer Ocean Health Supplements in Singapore	02-06	CI
Hyphens Pharma International Grants Nearly 6 Million Shares Under Performance Share Plan	12-11	MT
CGS-CIMB Adjusts Hyphens Pharma’s Price Target to SG$0.32 From SG$0.34, Keeps at Add	11-28	MT
Hyphens Pharma International Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Hyphens Pharma Unit Completes Purchase of First Tranche of Remaining Ardence Pharma Stake	11-08	MT
Hyphens Pharma to Acquire Remaining 58% Stake in Ardence Pharma	18/10/23	MT
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia	30/08/23	MT
Hyphens Pharma International Limited Announces Special Interim Tax Exempt (One-Tier) Dividend for the Financial Year Ending 31 December 2023, Paid on 31 August 2023	10/08/23	CI
Hyphens Pharma International Limited Reports Earnings Results for the Half Year Ended June 30, 2023	10/08/23	CI

Chart Hyphens Pharma International Limited

Duration

Period

Chart Hyphens Pharma International Limited

More charts

Company Profile

Hyphens Pharma International Limited is a Singapore-based specialty pharmaceutical and consumer healthcare company. The Company's principal activities are those of an investment holding company and provision of management services. The Company's segments include Specialty pharma principals, Proprietary brands, and Medical hypermart and digital. The Specialty pharma principals segment is engaged in the business of marketing and selling a range of specialty pharmaceutical products with exclusivity in the relevant ASEAN countries. The Proprietary brands segment is engaged in the business of developing, marketing and selling its own proprietary range of dermatological products and health supplement products. The Medical hypermart and digital segment is a wholesaler of pharmaceuticals and medical supplies in Singapore, which the Company and its subsidiaries position themselves as a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hyphens Pharma International Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.275 SGD

Average target price

0.35 SGD

Spread / Average Target

+27.27%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
HYPHENS PHARMA INTERNATIONAL LIMITED	-3.51%	62.55M
MCKESSON CORPORATION	+26.64%	76.05B
CARDINAL HEALTH, INC.	-3.02%	23.81B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+15.84%	8.8B
SINOPHARM GROUP CO. LTD.	+1.71%	8.29B
HUADONG MEDICINE CO., LTD	-32.22%	6.77B
H. LUNDBECK A/S	+19.23%	5.36B
GALENICA AG	+0.55%	4.06B
EBOS GROUP LIMITED	-9.44%	3.77B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	-7.80%	3.39B

Pharmaceuticals Wholesale